✦ LIBER ✦

Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII

✍ Scribed by H. Gelhorn; E. Merikle; S. Krishnan; L. Nemes; C. Leissinger; L. Valentino

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The perspective of patients with haemoph

✍ T. M. BROWN; C. L. PASHOS; A. V. JOSHI; W. C. LEE 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB

Unresponsiveness to factor VIII inhibito

✍ T. Hayashi; I. Tanaka; M. Shima; K. Yoshida; K. Fukuda; Y. Sakurai; T. Matsumoto 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Break-through bleeding in relation to pr

✍ P. W. COLLINS; V. S. BLANCHETTE; K. FISCHER; S. BJÖRKMAN; M. OH; S. FRITSCH; P. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 202 KB

Rituximab for the treatment of patients

✍ J. J. FIELD; T. S. FENSKE; M. A. BLINDER 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB

Pseudoprolongation of the Prothrombin Ti

✍ Marcus E. Carr; Jan G. Kuhn; Erika J. Martin; Ann R. Tidwell; Maura K. Hagane 📂 Article 📅 2003 🏛 Carden Jennings Publishing 🌐 English ⚖ 70 KB

The use of factor VIII/von Willebrand fa

✍ D. A. GRENINGER; J. M. SAINT-REMY; M. JACQUEMIN; A. BENHIDA; D. M. DIMICHELE 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB